Clinical Scorecard: Targeted Approaches and Precision Diagnosis in Neutrophilic Asthma: Exploring Molecular Mechanisms and Clinical Applications

At a Glance

Key Highlights

• Neutrophilic asthma is distinct from eosinophilic asthma, exhibiting glucocorticoid resistance.
• The Th17/IL-17 axis plays a central role in neutrophil recruitment and activation.
• Emerging therapies targeting IL-17, NET formation, and inflammasome components are in clinical development.
• Airway microbiome dysbiosis is implicated in the pathogenesis of neutrophilic asthma.
• A precision identification framework integrates molecular endotypes with clinical phenotypes.

Guideline-Based Recommendations

Diagnosis

• Identify neutrophilic asthma through sputum analysis showing ≥61% neutrophils.

Management

• Consider emerging therapies targeting IL-17 and NETs for treatment.

Monitoring & Follow-up

• Monitor neutrophil counts and IL-17 levels in patients with neutrophilic asthma.

Risks

• Patients may experience accelerated lung function decline and poor response to conventional glucocorticoid therapy.

Patient & Prescribing Data

Patients with neutrophilic asthma, particularly those with severe disease and glucocorticoid resistance.

Current therapies are limited; novel approaches targeting specific pathways are under investigation.

Clinical Best Practices

• Utilize a precision medicine approach to tailor treatments based on molecular mechanisms.
• Incorporate biomarker profiles in therapeutic decision-making.

Related Resources & Content